Er Therapeutics Stock Forward View
| PNGM Stock | USD 0.0001 0.00 0.00% |
PNGM Stock outlook is based on your current time horizon. Although Er Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we suggest always cross-verifying it against solid analysis of Er Therapeutics' systematic risk associated with finding meaningful patterns of Er Therapeutics fundamentals over time.
As of now the relative strength momentum indicator of Er Therapeutics' share price is below 20 indicating that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Using Er Therapeutics hype-based prediction, you can estimate the value of Er Therapeutics from the perspective of Er Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Er Therapeutics on the next trading day is expected to be -0.0004 with a mean absolute deviation of 0.0003 and the sum of the absolute errors of 0.02. Er Therapeutics after-hype prediction price | USD 6.1E-5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Er Therapeutics to cross-verify your projections. Er Therapeutics Additional Predictive Modules
Most predictive techniques to examine PNGM price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for PNGM using various technical indicators. When you analyze PNGM charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Er Therapeutics Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Er Therapeutics' financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2010-12-31 | Previous Quarter 317.7 | Current Value 301.82 | Quarterly Volatility 829.21306354 |
Er Therapeutics Naive Prediction Price Forecast For the 3rd of February
Given 90 days horizon, the Naive Prediction forecasted value of Er Therapeutics on the next trading day is expected to be -0.0004 with a mean absolute deviation of 0.0003, mean absolute percentage error of 0.00000017, and the sum of the absolute errors of 0.02.Please note that although there have been many attempts to predict PNGM Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Er Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Er Therapeutics Stock Forecast Pattern
| Backtest Er Therapeutics | Er Therapeutics Price Prediction | Research Analysis |
Er Therapeutics Forecasted Value
In the context of forecasting Er Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Er Therapeutics' downside and upside margins for the forecasting period are 0.000001 and 12.31, respectively. We have considered Er Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Er Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Er Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 102.5472 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 3.0E-4 |
| MAPE | Mean absolute percentage error | 1.6877 |
| SAE | Sum of the absolute errors | 0.0181 |
Predictive Modules for Er Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Er Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Er Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Er Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Er Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Er Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Er Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Er Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Er Therapeutics' historical news coverage. Er Therapeutics' after-hype downside and upside margins for the prediction period are 0.00 and 12.31, respectively. We have considered Er Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Er Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Er Therapeutics is based on 3 months time horizon.
Er Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Er Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Er Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Er Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.58 | 12.31 | 0.00 | 1.01 | 5 Events / Month | 1 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.0001 | 0.000061 | 38.76 |
|
Er Therapeutics Hype Timeline
Er Therapeutics is at this time traded for 0.0001. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 1.01. PNGM is forecasted to decline in value after the next headline, with the price expected to drop to 6.1E-5. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -38.76%, whereas the daily expected return is at this time at -1.58%. The volatility of related hype on Er Therapeutics is about 1932.5%, with the expected price after the next announcement by competition of 1.01. The company had not issued any dividends in recent years. Er Therapeutics had 3:1 split on the 13th of April 2009. Given the investment horizon of 90 days the next forecasted press release will be in about 5 days. Check out Historical Fundamental Analysis of Er Therapeutics to cross-verify your projections.Er Therapeutics Related Hype Analysis
Having access to credible news sources related to Er Therapeutics' direct competition is more important than ever and may enhance your ability to predict Er Therapeutics' future price movements. Getting to know how Er Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Er Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| VRCV | Varca Ventures | 0.00 | 0 per month | 0.00 | (0.13) | 0.00 | 0.00 | 95.00 | |
| SLSDF | Select Sands Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| PRMO | Prom Resources | 0.00 | 0 per month | 15.39 | 0.15 | 44.93 | (25.71) | 249.05 | |
| AGSVF | Argentum Silver Corp | 0.00 | 0 per month | 0.00 | 0.12 | 0.00 | 0.00 | 3,585 | |
| AOVTF | Andover Mining Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DBGF | Panex Res | 0.00 | 2 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| AGYP | Allied Energy | 0.00 | 0 per month | 17.91 | 0.15 | 100.00 | (50.00) | 150.00 | |
| IGNE | Igene Biotechnology | 6.37 | 17 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TINO | Tamino Minerals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MURCF | Lightspeed Discoveries | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Forecasting Options for Er Therapeutics
For every potential investor in PNGM, whether a beginner or expert, Er Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. PNGM Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in PNGM. Basic forecasting techniques help filter out the noise by identifying Er Therapeutics' price trends.Er Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Er Therapeutics stock to make a market-neutral strategy. Peer analysis of Er Therapeutics could also be used in its relative valuation, which is a method of valuing Er Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Er Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Er Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Er Therapeutics shares will generate the highest return on investment. By undertsting and applying Er Therapeutics stock market strength indicators, traders can identify Er Therapeutics entry and exit signals to maximize returns.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
Er Therapeutics Risk Indicators
The analysis of Er Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Er Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting pngm stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 74.65 | |||
| Standard Deviation | 308.14 | |||
| Variance | 94949.12 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Er Therapeutics
The number of cover stories for Er Therapeutics depends on current market conditions and Er Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Er Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Er Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Check out Historical Fundamental Analysis of Er Therapeutics to cross-verify your projections. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Will Diversified Metals & Mining sector continue expanding? Could PNGM diversify its offerings? Factors like these will boost the valuation of Er Therapeutics. Anticipated expansion of PNGM directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Er Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Er Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Er Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Er Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Er Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Er Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Er Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.